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This paper shows the scale of global health research and the context in which we frame the subsequent papers in the
Series. In this Series paper, we provide a historical perspective on clinical trial research by revisiting the 1948
streptomycin trial for pulmonary tuberculosis, which was the first documented randomised clinical trial in the
English language, and we discuss its close connection with global health. We describe the current state of clinical trial
research globally by providing an overview of clinical trials that have been registered in the WHO International
Clinical Trial Registry since 2010. We discuss challenges with current trial planning and designs that are often used in
clinical trial research undertaken in low-income and middle-income countries, as an overview of the global health
trials landscape. Finally, we discuss the importance of collaborative work in global health research towards generating
sustainable and culturally appropriate research environments.

Introduction
The field of global health prioritises improving health
and achieving health equity for all. Research in this area
is focused on improving health outcomes and addressing
inequities in low-income and middle-income countries
(LMICs).1,2 LMICs continue to have comparatively higher
rates of and burden from infectious diseases and other
communicable diseases (eg, HIV, malaria, diarrhoeal
diseases, and sepsis) than do high-income countries
(HICs). Among many health challenges, shorter life
expectancy and higher rates of maternal and child
mortality in LMICs, relative to HICs, have delayed their
developmental and economic potential.3–5 Thus, inter
ventions to reduce disease and improve health in LMICs,
particularly, should be a global priority.
Progress has been made in the prevention and
treatment of infectious diseases and other com
municable diseases, with randomised clinical trials
(RCTs) having been used to generate evidence on the
effectiveness of important therapeutics. RCTs are
considered robust methods for evaluating the
effectiveness of therapies because these studies fulfil the
primary assumption of statistical testing—ie, the
equality of treatment by minimising selection bias and
creating groups that are comparable in prognostic
factors—thereby establishing a causal effect of the
treatment on the outcome.6,7 RCTs are an important
methodological tool in global health research for
generating high-level evidence to inform the
development of context-specific and international
guidelines on preferred interventions that can be
delivered at scale to populations in need.5
Although the challenges in reducing the burden of
communicable diseases in LMICs are considerable,
there have been important demographic and epidemio
logical shifts occurring rapidly in LMICs. The global
population is estimated to increase from approximately
www.thelancet.com/lancetgh Vol 9 May 2021

7·7 billion people in 2019, to 8·5 billion by 2030, and
further to 9·7 billion people in 2050.6 The most rapid
growth is projected to occur in sub-Saharan Africa, with
the population size expected to double by 2050.6 With the
increasing life expectancy in LMICs, there will be a
consequent increase in the burden of non-communicable
diseases (NCDs), because these diseases are more
common in adults older than 65 years.7–9 This rapid
change in population size and demographics, in addition
to the rising burden of NCDs, presents many challenges
for meeting the Sustainable Development Goals.8–10
A change in approach is needed to rapidly answer
research questions that can accompany the changes
in demographics and disease burden in LMICs, where
Key messages
• Low-income and middle-income countries face the most
rapidly occurring demographic and epidemiological
transitions globally that threaten sustainable global
development.
• Clinical trial research has an inherent connection with
global health research that aims to answer important
questions for populations in need, but there is a mismatch
in clinical trial efforts and disease burden globally. Of the
324 854 randomised clinical trials that have been
registered from 2010 to 2019, our analysis has shown that
only 17 777 (5%) of the trials were set in south Asia and
only 5756 (2%) of the trials were set in sub-Saharan
African countries.
• Clinical trials that are undertaken in low-income and
middle-income countries can be improved by promoting
new methodological innovations that can be leveraged to
improve the ability of the local regions across low-income
and middle-income countries to sustain research
infrastructure and human resources for long-term gains.
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resources are limited and health research capacity is
low. In the current era, efficient research designs
that can answer multiple complex research questions
simultaneously with a minimised sample size and trial
duration will be beneficial, but there are also many
logistical and methodological barriers to overcome
before such an approach is a reality.
This paper in the Series reviews the close connection
of global health with methodological research. We
summarise the current landscape of global health trial
research, the limits of conventional approaches to trials,
and challenges in trial planning.

History of RCTs
Global health research is inherently connected to clinical
trials. Sir Austin Bradford Hill advocated for RCTs for at
least a decade before the first peer-reviewed RCT in the
English language was published in 1948.11–13 According
to Bradford Hill, the concept of randomisation was
extraneous to the individuals of the medical community
in the UK, many of whom rejected the notion at the
time.13
The 1948 streptomycin trial for pulmonary
tuberculosis from the UK Medical Research Council11
changed the landscape of medicine and public health.
The trial was done shortly after World War 2, a time of
immense resource limitations and widespread illness
and injuries.13 The war had effectively stripped the UK
of financial resources and the government could only
afford to purchase streptomycin, a new drug for treating
tuberculosis, for only 55 patients.13,14 Economic hardship
was a dominant reason that made this RCT possible.
The high burden of tuberculosis and scarce drug
resources justified the UK Medical Research Council
in using an RCT, to ensure the fair distribution of
a scarce drug supply and to obtain a reliable answer
regarding the effectiveness of streptomycin for treating
tuberculosis.11,13,15
In the seven decades since, the pharmaceutical industry,
particularly in the area of oncology research, has made
several important advancements in statistical analysis,
simulation methods, and outcome assessments for
innovative designs, such as adaptive trial designs and
master protocols.16–19 These innovative designs have
also been used, although scarcely, in specialised fields,
such as clinical neonatology.19,20 However, uptake of these
methods has been poor in global health research,21,22 much
like the situation in which the medical community was
initially reluctant to embrace the concept of randomisation
less than a century ago. With the increasing challenge of
the double burden of NCDs and communicable diseases
in the context of global health, questions to be answered
are manifold and more complex; however, human
resources and research infrastructure in LMICs are
limited. Adopting methodological innovations to clinical
trial design and implementation has the potential to bring
the efficiency needed to global health research.

Current landscape of trial research in global
health
Although any definition of global health is contentious, in
this Series, we will refer to global health research as any
clinical research undertaken in a collaboration between
researchers in HICs and LMICs, in which most intended
monetary funding comes from outside of the country that
the research is conducted in. This definition recognises
the potential power imbalance among researchers and
among sponsoring institutions. Throughout this Series,
we discuss several limitations of current, possibly
inefficient and often outdated, approaches to trial design,
but it is important to note that these criticisms apply
equally to all those working in global health research,
including (or potentially predominantly) researchers in
HICs designing these studies and the funders sponsoring
them, in light of these power imbalances.

Mismatch between research efforts and disease burden
There is a well recognised mismatch between research
efforts (eg, number of clinical trials) and disease
burden.23 Despite public health efforts to minimise
disparities in health, research efforts have largely been
focused towards the interests of HICs (eg, the USA
and the UK), particularly in markets for which high
commercial interests and sustained public funding
exist. Several studies have shown that most clinical
trial research is undertaken in HICs.23–26 According to
the WHO International Clinical Trial Registry, as of
Nov 5, 2019, RCTs in LMIC settings have only accounted
for 109 713 (32%) of 342 854 RCTs registered worldwide
(figure 1). Despite 24% (1·8 billion people estimated for
2019) of the global population currently residing in
south Asia, this region is the setting of only 5% (n=17 777)
of all RCTs worldwide.6 Sub-Saharan African countries
(which had a population of 1·1 billion people in 2019)
are the setting of an even smaller proportion of RCTs, at
2% (n=5756).6
The low number of RCTs represents a missed
opportunity for LMICs and suggests the need for more
clinical trial research in global health. When global health
clinical trials are undertaken, they are often done with
insufficient funding to support sustained development of
research infrastructure and human resources in the
LMICs in which they are set. To maintain clinical trial
research efforts in global health over the long term, the
ability to sustain research infrastructure and human
resources for local settings through consolidated and
minimised single-use research activities related to trial
planning and execution is crucial.
Efforts to support local ownership and coproduction
of health research in LMICs are rare.27 In key topical
fields of global health research, such as HIV and AIDS,
malaria, and tuberculosis, there is a low first-authorship
of researchers from LMICs on publications, raising a
concern of rare opportunities for research, career advance
ment, and capacity building for LMIC researchers.28
www.thelancet.com/lancetgh Vol 9 May 2021
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Importance of location and context
The world is often dichotomised into the industrialised
world versus the developing world. In global health
research, there are often tendencies to ignore the
different contextual factors between different LMICs and
to search for common interventions that will improve
health across multiple countries in many diverse
populations.29 However, the reality is that there is often
no one-size-fits-all solution because there is substantial
heterogeneity between and within different countries.30
Different biological and socioeconomic factors of the
trial location should be considered during the planning
stage, to determine whether the research question is
being asked in the right setting. For instance, despite a
total of 168 460 neonates having been studied across
12 trials in LMICs, a 2017 Cochrane review by Haider
and colleagues31 reported inconclusive evidence for
neonatal vitamin A supplementation on infant mortality.
There were conflicting findings between different
individual studies that had importantly different rates of
maternal vitamin A deficiency and infant mortality.31 It
is ill-advised to undertake clinical trials on vitamin
A supplements among populations with low or no
vitamin A deficiency. If these resources had instead been
allocated to undertaking trials in regions where the
prevalence of vitamin A deficiency is high, it is likely that
there would be more conclusive evidence to support or
refute the benefits of vitamin A supplementation on
infant mortality.
It is beneficial if biological samples are collected,
to better understand the biological mechanisms of differ
ent interventions. Biological information can become
especially important when the statistical assessment of
the clinical outcomes show no difference. Collection of
biological samples allow for mechanistic analyses to be
undertaken alongside the main analyses of clinical trials,
to better understand what happens biologically when an
intervention is given. If laboratory analyses can show no
biological associations, negative trial results could mean
that the intervention probably does not have the initial
hypothesised effects.29
In addition to biological analyses, consideration of
clinical events that occur after a given intervention is
initiated (ie, intercurrent events) is important. Intercurrent
events, such as discontinuation of intervention, switching
intervention, and use of rescue medications, are often
handled with simple intention-to-treat (ITT) analyses.32
The ITT principle is intended to measure the effective
ness of intervention in real-world conditions, in which
participants will not adhere perfectly to the protocol.33,34

Figure 1: Global overview of clinical trial research
(A) Percentage of registered randomised clinical trials worldwide. (B) Percentage
of trials that are cluster-randomised, by country, from the WHO International
Clinical Trials Registry Platform from Jan 1, 2010, to Nov 5, 2019. (C) Number of
master protocols registered or undertaken worldwide as of Dec 11, 2019.21
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However, the intercurrent events can increase the
variability of the data and make interpreting the study
findings difficult. For instance, with the ITT principle, the
discontinuation of an intervention is often ignored in the
main analysis even though this action will affect the
clinical outcomes of the participants in the study. Given
that ITT analysis is used as the main primary analysis,
different analytical strategies to handle discontinuation of
intervention or other intercurrent events as sensitivity
analyses are beneficial to explore the robustness of the
ITT analysis.33,35

Affinity towards conventional designs
In global health research, conventional fixed trial
designs are most often used for clinical research. Fixed
trial designs refer to a type of design in which the trial
data are analysed only once, when the trials are finished,
after determining a sample size a priori.36,37 Fixed trial
designs do not plan for any modifications to major
design components (eg, sample size, allocation ratio,
and number of interventions) throughout the trial.36–38
In clinical trials, data are accumulated over time, and
some clinical trials might take years to complete. Fixed
trial designs do not permit learning during the trial
from the accumulating trial interim data because the
interim data are not analysed throughout the trial.
Investigators usually make assumptions about the
population, inter
ventions, outcomes, and other trial
parameters on the basis of information that is available
at the planning stage, and continue these assumptions
throughout the trial until the last participant has
completed their follow-up.
It is difficult to determine why methodological
advancements in clinical trials have been slow to develop
or gain acceptance in global health research. Advocacy
for clinical trial education in LMICs has predominantly
occurred via academic medical journals. The leading
journals have published widely on methodological issues
advocated by expert groups, such as the Consolidated
Standards of Reporting Trials, Grading of Recom
mendations, Assessment, Development, and Evaluation,
and Cochrane collaborations, which have historically
placed a primacy on individual quality indicators of
clinical trials. These quality indicators have examined
issues that can affect the precision of trial estimates and
their likelihood of introducing bias. However, scoring
the quality of clinical trials can be misleading and
potentially hazardous if clinical decisions or public
health decisions are influenced by evidence that could
later be contradicted.39 Many of the methodological
features that are considered key to determining the
quality of a trial, including blinding, reporting of ITT
analysis, allocation concealment, and sequence genera
tion, have clear benefits, but there are issues with these
features when evaluating whether randomised trials with
a different design should be considered in policy making;
a more nuanced approach is needed, given that there
e684

have been inconsistent findings as to whether these
features are actually important to biasing study results.40,41
However, these features are still routinely taught and are
embedded in WHO guideline evaluations to determine
whether guidelines provide strong evidence or not. The
global health community could benefit from gaining an
understanding of more innovative methods that are now
available.
In the past few decades, important methodological
advancements, particularly in adaptive trial designs,
have sought to offset limitations that conventional
trial designs can pose.17,42 An adaptive trial design, an
extension of conventional fixed trial designs, is a type of
trial design that allows for prespecified modifications (or
adaptations) to the trial design during the trial, including
plans for interim evaluations and decision rules.16,17,37
Adaptive trial designs do not necessarily impose modifi
cations to a trial: if prespecified decision rules are not
met according to the trial data, the trial would continue
without any adaptations and function as if the trial
had a fixed trial design (figure 2). In brief, an adaptive
trial design is a data-driven approach to a clinical trial
investigation that allows trial modifications before an a
priori sample size target has been reached.
Common examples of adaptive trial designs include
group sequential designs and sample size reassess
ment.17,37,38 A group sequential design is a type of design
that allows for early stopping with stopping rules, usually
based on a frequentist statistical metric in test statistics
(typically p value boundaries).17,43 If the interim data
assessment shows crossing of stopping boundaries, then
the trial might stop under a group sequential design.
With more frequent observations, inflation of type I error
rates can occur (multiplicity), especially without statistical
adjustments. In a commonly used group sequential
design, such as the O’Brien-Fleming approach, the
stopping boundaries are set more stringently with more
interim analyses to preserve a significance level for the
final analysis that is close to the significance level of a
single analysis (eg, 5% α).43 Sample size reassessment is
another type of adaptive trial design that allows for an
increase in sample size based on interim data.17,38 Sample
size reassessment was developed to mitigate risks for
false-negative findings.
Although adaptive trial designs have received substantial
attention in recent years, they are not without limitations.
Every clinical question deserves a thorough investigation
and consideration of the pros and cons when selecting
design options and there should be no default design
choice. An efficient trial design for one research question
can be inefficient for another. Undertaking smarter trials
requires a thorough consideration of multiple candidate
designs during the planning stage, ideally with the use of
statistical simulations to weigh the efficiencies of different
designs. Further discussion of adaptive trial designs and
case studies are provided in the second44 and fourth45
papers of this Series.
www.thelancet.com/lancetgh Vol 9 May 2021
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Inadequate planning practices
Often in global health research, very little information is
available regarding epidemiology and infrastructure in the
context of the investigation, which can make trial planning
difficult. Sample size calculations are a key challenge
due to the unfamiliarity with regard to local epidemiology
and expected treatment effects or accepted minimally
clinical important difference. The recommended process
of determining a realistic or important target difference
between treatments has previously been described in the
difference elicitation in trials (also known as DELTA²)
guidance.46
Sample size calculations are a simplistic form of
simulating a trial, and sample size calculations for RCTs
with dichotomous outcomes require prespecification of
operating characteristics, event rates in the control and
intervention groups (ie, desired or expected effect sizes),
and the rate of loss to follow-up. In most research
areas within global health, operating characteristics are
usually selected by convention at 80% statistical power
and 5% type I error rate. There are no conventions
for selecting event and treatment effect parameters
when investigating dichotomous or other outcomes
(eg, continuous and count outcomes). Clinical trials are
often underpowered even when the planned sample size
is reached due to erroneous assumptions used for sample
size calculations, such as lower incidence of events than
planned and lower treatment effects than anticipated. At
the other extreme, the trial could be overpowered and
too many participants might be recruited into a given
trial, wasting time and resources.38 Consequently, the
development of essential guidance might be delayed
because another trial is required, or because the original
trial has taken longer than necessary.
Appropriate sample size calculations are dependent on
correct assumptions of design parameters. Often in
global health research, clinical trials are planned on the
basis of nationally representative cross-sectional survey
data, such as Demographic and Health Surveys and
Multiple Indicator Cluster Surveys, which monitor and
evaluate programme implementation at a national level.47
Although these cross-sectional surveys are valuable for
these purposes, their use for trial planning, including
sample size calculations, can be limited. These surveys
fail to show temporal variability that might exist in
disease severity because these cross-sectional surveys
are not undertaken annually; Demographic and Health
Surveys are typically carried out every 5 years48 and
Multiple Indicator Cluster Surveys are carried out every
3 years.49 Additionally, these surveys report on the national
or regional prevalence of disease, and not the incidence,
and can miss important geographical or demographic
heterogeneity.
Assumptions used for sample size calculations can
also be based on findings from previous studies. The use
of a thorough literature review is important to identify
reliable estimates; however, making such assumptions
www.thelancet.com/lancetgh Vol 9 May 2021
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Figure 2: Conventional fixed trial designs and common adaptive trial designs
(A) A two-arm randomised clinical trial with conventional fixed trial design.
(B) A two-arm trial with SSR. If the first interim analysis shows worse results
than expected, an SSR can be carried out by use of the interim results. An SSR is
not permitted in a traditional non-adaptive trial, so even when the original
planned sample size is reached, the trial might be underpowered. If SSR is
permitted, the sample size could be increased to ensure that the trial is
adequately powered. (C) A two-arm trial with response adaptive
randomisation. The response adaptive randomisation design allows for
preferential assignment of interventions that show favourable interim results.
In this example, the response adaptive randomisation design allows for an
increased allocation ratio to treatment 1 based on the interim results.
SSR=sample size reassessment.

by extrapolation from previous studies can also have
limitations. Researchers must account for how similar
(or dissimilar) a previous study is to the trial being
planned, including the recency of the study findings, or
geographical and demographic differences. Even when
there are recently undertaken studies with geographical
and demographic similarities, there are still possibilities
of having unexpected findings (panel).
However, sample size calculations are only a small
part of efficient trial planning. A thorough consideration
of all accessible scientific knowledge and exploration
of multiple scenarios to anticipate potential risks and a
range of expected results is also required in the planning
stage.37 This approach can be achieved by use of compu
tational simulations of study results under various
scenarios that test the fragility of assumptions and weigh
the pros and cons of different candidate design strategies
for smarter trial planning.53 Despite its importance, only a
few examples of clinical trials incorporating simulations
exist in global health research.54–56

Cluster trial designs
Cluster-randomised trials are a type of clinical trial
that involve randomisation of groups or clusters of
e685
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Panel: A rural Tanzania-based cluster trial studying the efficacy of topical repellent on
malaria transmission (ISRCTN92202008)
Between July, 2009, and August, 2010, a placebo-controlled cluster trial was undertaken
in a rural village in Tanzania (Mbingu village of the Ulanga district) to evaluate the
efficacy of topical repellent on reducing malaria transmission.50 After sample size
calculation, it was determined that enrolling 10 clusters of 47 households (each with five
family members) would yield 90% statistical power at a 5% type I error rate, assuming a
30% control event rate of evening malaria transmission (primary outcome) and a
treatment effect size of 80% risk reduction.50
Several assumptions were made to justify the 30% control event rate for sample size
calculation, given that there were no available estimates of malaria transmission in this
region.50 The trial investigators assumed a malaria incidence rate of 1·0 malaria case per
person per year on the basis of available estimates of fever incidence rate among children
younger than 5 years (3·2 cases per person per year51), under the assumptions that only a
proportion of fevers are caused by malaria and that the village population would be less
prone to fevers than children.50 Because it has been previously estimated that 30% of
mosquito bites occur in early evenings,52 the trial investigators justified the control event
rate of 30% by combining the assumed malaria incidence rate with the proportion of
evening mosquito bites.50
During the trial, Tanzania had a drought that reduced the malaria transmission rate, which
led to a lower control event rate, meaning that the trial became underpowered due to the
drought. This trial did not identify any benefits of topical repellent in malaria transmission
reduction. The investigators have attributed the negative effects to the lower malaria
infection rate, because only a 6% infection rate was identified in the trial instead of the
anticipated 30% infection rate.50 Despite the unexpected challenges that occurred, this trial
continued until its intended completion date as originally planned, with 4426 individuals
being enrolled.50 When observed control event rates are considerably lower than the rates
anticipated for initial trial planning, clinical trials, in turn, will be underpowered and there
will be little (or no) promise of providing conclusive answers. To anticipate for such
instances, prespecifying mechanisms of applying a futility analysis through adaptive trial
designs could be useful.

participants, rather than individuals.57 Cluster trials are
appropriate for settings in which the use of individual
randomisation is not feasible due to the nature of
interventions being evaluated or in which substantial
contamination is unavoidable. Cluster trials might also be
used in cases for which the final aim is to evaluate the
effectiveness of interventions at a mean cluster level.57
Therefore, such trials are useful for evaluating the
effectiveness of interventions or practices at the population
level. For instance, in the early 1990s, several cluster trials
were undertaken to determine the effects of insecticidetreated bednets for malaria prevention,58–62 because testing
these bednets in patient-level RCTs would not have been
feasible. These cluster trials have provided strong evidence
for the effectiveness of insecticide-treated bednets, a core
component of malaria prevention efforts in LMICs.63
Compared with HICs, cluster trials are more
frequently undertaken in LMICs even though there are far
fewer RCTs undertaken (figure 1). In HICs, cluster RCTs
are undertaken relatively infrequently, with only
1657 (0·72%) cluster trials of all 231 477 trials documented;
by contrast, the proportion of cluster trials is more than
e686

doubled in south Asia (308 [1·73%] cluster trials of all
17 777 trials) and eight times higher in sub-Saharan Africa
(354 [6·04%] cluster trials of all 5859 trials). Although
there are instances in which cluster trials are appropriate
(eg, when interventions cannot be delivered at the
individual level), it is important to note that cluster trials
can be expensive to carry out due to their statistical
inefficiencies. Because the observations of individuals
within the same cluster are usually correlated, there
are statistical inefficiencies associated with cluster
randomisation. To achieve statistical control of the
probability of false-negative risks and false-positive risks
(eg, 80% statistical power and 5% type I error rate), cluster
trials require a much larger number of participants than
individually randomised trials. Detailed discussions of
cluster trial designs in the context of global health are
provided in the third paper64 of this Series.

Factorial trial designs
Factorial clinical trials are a type of clinical trial that
simultaneously test the effect of two or more interventions
with the use of various combinations of interventions.65
For instance, in a two-by-two factorial trial design,
participants or clusters are randomised to one of the four
combinations of two interventions (eg, A and B); the
combination of these intervention strategies (A alone, B
alone, and A plus B combined) can be compared against a
control arm that does not receive intervention A or B.
Factorial trial designs can be appealing because two or
more interventions can be assessed at the same time in the
same population simultaneously.66 Assuming that there is
no interaction between the interventions, factorial designs
can be an efficient way to test multiple interventions.
Factorial designs can also allow for the testing of treatment
interactions, but, depending on treatment interaction
effects, these designs can result in sample sizes often four
times higher than a comparable two-arm trial.66 To
undertake efficient factorial clinical trials, it is important to
have a reliable estimate of the treatment interaction effects.
Such estimations can be challenging because reliable
estimates regarding treat
ment interaction often do not
exist. Treatment inter
action estimates are essential for
determining sample size requirements because inter
actions can substantially increase the needed sample size.
Implementing factorial trials can also be more operationally
challenging than two-arm trials because such trials usually
involve multiple arms.

Building on long-term research infrastructure
and capacity in global health
There is a need to build long-term research infrastructure
and capacity in LMICs for long-term sustainability.67,68 In
the context of global health, limited infrastructure and
capacity in some regions can pose a challenge in carrying
out clinical research.69 However, it is important to
recognise that some regions have not been given a longterm opportunity to build and sustain an infrastructure
www.thelancet.com/lancetgh Vol 9 May 2021
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that would also allow for local training and professional
development to be improved. There is a need to grow a
large network of competent research groups by
dedicating long-term funding for infrastructure and
professional development, while ensuring that LMIC
investigator-initiated or institution-initiated trials that
aim to provide answers to local priorities have precedence.
The adoption and application of data-driven
methods (eg, adaptive trial designs) has been scarce in
global health research,70–74 despite their potential to save
resources, improve the chance of identifying effective
interventions, and address certain ethical concerns.
Additionally, long-term trials that test multiple inter
ventions with the use of a common control under a
master protocol framework—perhaps the most efficient
of all trial designs—have mainly been done in HICs, and
not in LMICs (figure 1).21,22 A master protocol refers to a
framework in which clinical trial research is undertaken
with an overarching design that has been developed to
evaluate multiple hypotheses with the aims of improving
efficiency and establishing uniformity through stan
dardisation of procedures in the development and
evaluation of interventions.18,75,76 Master protocols can
differentiate into multiple parallel substudies to
include standardised trial operational structures, patient
recruitment and selection, data collection, analysis, and
management.18,75,76 In LMICs, adopting the framework of
master protocols could be one way forward towards
improving the coordination and sustainability of clinical
research efforts in the global health field.
Clinical trial research in global health can often be
fragmented and uncoordinated with a preponderance of
short-term two-arm trials that have low statistical power
and are small in scale. This preponderance of two-arm
trials that have low statistical power can be attributed to a
scarce funding availability, in which investigators
compete for a small pool of funds. Funders rarely
collaborate, and there might be little incentive for greater
collaborations of researchers in geographical regions
beyond their existing professional networks. This norm
of short-term funding gives little room to consider
building local infrastructure and human expertise. When
these short-term trials finish, the infrastructure often
disappears along with the data generated from research
and the investigators who brought the funds from HICs,
and investigators based in the country and who actively
participated in the research are frequently omitted in
peer-reviewed publications.28,77–79
To build a lasting research capacity in LMICs in a
sustainable manner, equitable collaboration with the
local researchers is needed. This collaboration, of course,
should include fair equitable representation of local
researchers from peer-reviewed publications and fair
allocation of funds with local institutions. Collaboration
between existing or newly established clinical trial
networks (eg, AIDS Clinical Trials Group and European
and Developing Countries Clinical Trials Partnership)
www.thelancet.com/lancetgh Vol 9 May 2021

should also be fostered and incentivised to allow for the
exchange of ideas, supervision, and mentorship between
different places, markets, or people that can facilitate the
securing of resources and training, as well as educational
opportunities in innovative trials designs, to ensure that
efficient clinical trial research can be undertaken in a
sustainable manner for global health.80–82
For example, maternal, newborn, and child health is
one area in the field of global health that has seen
fragmented and uncoordinated efforts, despite having
clear and specific global targets set of reducing low
birthweight by 30% and stunting in children younger
than 5 years by 40% globally.83–85 The clinical trial evidence
remains weak for interventions aimed at reducing
adverse birth outcomes and child stunting in the first
1000 days of life.86–88
A 2019 systematic review identified 169 RCTs in LMICs
(comprising 302 061 participants) that evaluated the
comparative efficacy of interventions under multiple
domains of micronutrient and balanced energy protein
or food supplements, deworming, maternal education,
water sanitation, and hygiene during preg
nancy,
exclusive breastfeeding, and complementary feeding
periods (ie, the first 1000 days of life; appendix p 2).89 For
this key global health priority, 86 (51%) of 169 of these
trials were of 26 weeks in duration or shorter, 69 (41%) of
169 of the trials recruited fewer than 500 patients, and
101 (60%) of 169 of the trials were not statistically
conclusive on important clinical outcomes.89
Most of these trials were either single-centre trials
or the trials had recruited patients from a few centres
in the same country or region, usually around the
capital city or a nearby region. Because clinical trials
are often undertaken to estimate the population-level
effects of given interventions, the norm of carrying out
single-centre trials can be problematic for global health
research. Geographical variation cannot be shown when
trials are undertaken in a small number of centres and
random effects of interventions arising from geographical
variability cannot be estimated (appendix pp 3–4). If the
intervention being investigated truly has no effects at the
population level (null effects), the intervention might still
show positive treatment effects if the trial is undertaken
at one centre by play of chance. Trials carried out in this
way would result in an inflated type I error rate because,
in these single-centre trials, other locations that would
show negative effects (which would cancel out the
positive effect from the one centre with this finding) are
omitted. Conversely, if the intervention does have a true
positive treatment effect at the population level, an
opposite effect (ie, failing to show an effect for an effective
treatment) might be observed due to the use of a location
that shows null or negative effect by chance. Thus,
undertaking single-centre trials might result in a lower
statistical power than multicentre trials.
All of these trials used fixed trial designs, even though
well planned interim evaluations could have ended

See Online for appendix
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the trials for reasons of superiority or futility and
saved resources for other research. Interim analyses
can also help protect participants. Early stopping
for superiority could translate to early dissemination of
effective interventions, and early stopping for futility
could minimise unnecessary exposure to participants.
The current evidence would arguably be stronger if the
resources that were invested towards these multiple
small two-arm clinical trials had been diverted into a few
larger multi-arm trials with adequate statistical power
and trial planning. Combined resources could also have
allowed for the collection of biological samples
and sociocultural data to better characterise the study
context and, thus, allow for an improved understanding
of the mechanism of interventions.29 We continue the
discussions for interim analyses for early stopping and
the framework of master protocols for global health in
further detail in the second44 paper of this Series.

Conclusion
Clinical trial research has had a strong connection to
global health that aims to improve health equities for
populations that have a high burden of disease. Clinical
trial research has identified many essential interventions
for communicable diseases in LMICs but, with many
LMICs rapidly transitioning into an NCD era, and with
shortages of necessary funding for research, serious
challenges await. The global health trial landscape
has remained largely static over the past 70 years, with
few examples of new methodological innovations being
adopted. In the second paper of this Series, we outline
new methods and tools that can be used to improve the
efficiency and quality of global health clinical trials.
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